

APPLICANT FACSIMILE OF FORM PTO-1449 REV 7-90		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY DOCKET NO CME-083CPCN	SERIAL NO 09/469,637
LIST OF PUBLICATIONS CITED BY APPLICANT (Use several sheets if necessary)				APPLICANT Marsha A. Moses et al.	
FILING DATE December 22, 1999				GROUP 1651	



U. S. PATENT DOCUMENTS

CLASS	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
26	5,270,447	12/93	Liotta et al.	530	326	
AB	5,324,634	06/94	Zucker	435	7.23	
AC	5,344,760	09/94	Harvey et al.	435	7.5	
AD	5,482,848	01/96	Dickson et al.	435	219	

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
26	AE 685 557	06/95	EPO				
	AF 691 409	10/96	EPO				
	AG WO 90/10228	09/90	PCT				
	AH EP 0 430 642	06/91	EPO				
	AI WO 91/11714	08/91	PCT				
	AJ JP 03 290 199	12/91	Japan			abst	
	AK WO 92/01936	02/92	PCT				
	AL WO 94/25434	11/94	PCT				
	AM WO 93/20447	10/93	PCT				

OTHERS (including Author, Title, Date, Pertinent Pages, Etc.)

26	AN	Attallah, A. et al., "Comparative Study Between Cytology and Dot-ELISA for Early Detection of Bladder Cancer", <i>A.J.C.P.</i> , Vol. 102, No. 1, pp. 109-114 (1996);
	AO	Basta, M. et al., "Cytokeratin Shedding in Urine: A Biological Marker for Bladder Cancer?", <i>British Journal of Urology</i> , Vol. 61, pp. 116-121 (1988);
	AP	Blaser, J. et al., "A Sandwich Enzyme Immunoassay for the Determination of Neutrophil Lipocalin in Body Fluids", <i>Clinica Chimica Acta</i> , Vol. 235, pp. 137-145 (1995);
	AQ	Bogdanowicz, J. et al., "Evaluation of Prostate-Specific Antigen and Prostatic Acid Phosphatase in Untreated Prostatic Carcinoma and Benign Prostatic Hyperplasia", <i>Scand. J. Urology Nephrol. Suppl.</i> , Vol. 138, pp. 97-103 (1991);
	AR	Braunhut, S. et al., "Retinoids Modulate Endothelial Cell Production of Matrix-degrading Proteases and Tissue Inhibitors of Metalloproteinases (TIMP)", <i>Journal of Biological Chemistry</i> , Vol. 259 (18):13472-13479 (1994);
	AS	Breul, J. et al., "Prostate-Specific Antigen in Urine", <i>Eur. Urol.</i> , Vol. 26, pp 18-21 (1994);

Examiner

R. G. G. G.

Date Considered

3/22/04

*EXAMINER

Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

APPLICANT FACSIMILE OF FORM PTO 1449 REV 7-89	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY DOCKET NO. CME-083CP	SERIAL NO. 08/843,095
PUBLICATIONS CITED BY APPLICANT (Use several sheets if necessary)		APPLICANTS Marsha A. Moses et al.	
		FILED DATE April 25, 1997	GROUP 1651

OTHERS (including Author, Title, Date, Pertinent Pages, Etc.)

RG	BA	Carr, M. et al., "Urinary Levels of the Renal Tubular Enzyme N-Acetyl-β-D-Glucosaminidase in Unilateral Obstructive Uropathy", <i>The Journal of Urology</i> , Vol. 151, pp. 442-445 (1994);
	BB	Fernandez-Luna, J. et al., "Measurement of Protein HC (α ₁ microglobulin) and protein HC-IgA complex in different body fluids", <i>J. Clin. Pathol.</i> , Vol. 41, pp. 1176-1179 (1988);
	BC	Fine, R., et al., "Accumulation of Urinary Cancer-related Glycoprotein, EDCI, in Psoriasis", <i>Journal of Investigative Dermatology</i> , Vol. 73, pp. 264-265 (1979);
	BD	Garnick, M., "Prostate Cancer: Screening, Diagnosis, and Management", <i>Annals of Internal Medicine</i> , Vol. 118, pp. 804-818 (1993);
	BE	Garnick, M., "The Dilemmas of Prostate Cancer", <i>Scientific American</i> , Vol. 270 (4), pp. 72-81 (1994);
	BF	Grover, P. et al., "Analysis of Prostatic Fluid: Evidence for the Presence of a Prospective Marker for Prostatic Cancer", <i>The Prostate</i> , Vol. 26, pp. 12-18 (1995);
	BG	Ho, K. et al., "Urinary Beta-Glucuronidase Activity as an Initial Screening Test for Urinary tract Malignancy in High Risk Patients", <i>Cancer</i> , Vol. 76, No. 3, pp. 473-478 (1995);
	BH	Jones, A. et al., "Urinary N-acetyl-β-glucosaminidase Activity in Type I Diabetes Mellitus", <i>Ann Clin Biochem</i> , Vol. 32, pp. 58-62 (1995);
	BI	Kossakowska, A. et al., "Tissue Inhibitor of Metalloproteinases-1 (TIMP-1) RNA Is Expressed at Elevated Levels in Malignant Non-Hodgkin's Lymphomas", <i>Blood</i> , Vol. 77 (11), pp. 2475-2481 (1991);
	BJ	Lee, M. et al., "Analysis of Affinity and Structural Selectivity in the Binding of Proteins to Glycosaminoglycans: Development of a Sensitive Electrophoretic Approach", <i>Biochemistry</i> , Vol. 88, pp. 2768-2772 (1991);
	BK	Liotta, L. et al., "Cancer Metastasis and Angiogenesis: An Imbalance of Positive and Negative Regulation", <i>Cell</i> , Vol. 64, pp. 327-336 (1991);
	BL	Lu, X. ET AL., "Immunological Quantitation of Levels of Tissue Inhibitor of Metalloproteinase-1 in Human Colon Cancer", <i>Cancer Research</i> , Vol. 51, pp. 6231-6235 (1991);
	BM	Margulies, I. et al. "Urinary Type IV Collagenase: Elevated Levels Are Associated with Bladder Transitional Cell Carcinoma" <i>Cancer Epidemiology, Biomarkers & Prevention</i> , Vol. 1, pp. 467-474 (1992);
	BN	Miller, D. et al., "Purification and Characterization of Active Human Interleukin 1β-converting Enzyme from THP.1 Monocytic Cells", <i>Journal of Biological Chemistry</i> , Vol. 268 (24), pp. 18062-18069 (1993);
✓	BO	Moses, M. et al., "Production of Matrix Metalloproteinases and a Metalloproteinase Inhibitor by Swarm Rat Chondrosarcoma", <i>Biochemical and Biophysical Research Communications</i> , Vol. 199 (1), pp. 418-424 (1994);

Examiner

RG TANCEN

Date Considered

3/24/04

EXAMINER

Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

CME-083CP

08/843.095

APPLICANTS

Marsha A. Moses et al

FILING DATE

April 25, 1997

GROUP

1657

OTHERS (including Author, Title, Date, Pertinent Pages, Etc.)

Paigen, B. et al., "Urinary Glucuronidase and Arylsulfatases in Identical Twins of Bladder Cancer Patients", *Cancer Research*, Vol. 44, pp. 3624-3626 (1984);

Robins, S. et al., "Direct, Enzyme-Linked Immunoassay for Urinary Deoxypyridinoline as a Specific Marker for Measuring Bone Resorption", *Journal of Bone and Mineral Research*, Vol. 9, No. 10, pp. 1643-1649 (1994);

Schmitt, M. et al, "Tumor-Associated Urokinase-Type Plasminogen Activator: Biological and Clinical Significance", *Biol. Chem.*, Vol. 373, pp. 611-622 (1992);

Tetzner, E. et al., "Österreichische Zeitschrift für Erforschung und Bekämpfung der Krebskrankheit", *Österr. Zschr. Krebsforsch.*, pp. 233-237 (1971) -(English Abstract Included);

Tomita, Y. et al. "Immunohistochemical Detection of Inter cellular Adhesion Molecule-1 (ICAM-1) and Major Histocompatibility Complex Class I Antigens in Seminoma", *Journal of Urology*, Vol. 149, pp. 659-663 (1993);

Woessner, J., "The Family of Matrix Metalloproteinases" *Annals New York Academy of Sciences*, Vol. 732, 11-21 (1994).

Examiner

Date Considered

*EXAMINER

Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

APPLICANT PAGEABLE OF FORM PTO-1449
REV 7-98

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY DOCKET NO

CMZ-083CPNCNPA

SERIAL NO

09/469

Sheet 1 of 1

APPLICANT

Moses, Marsha A. et al.

FILING DATE

February 20, 2002

GROUP

1623 / 651

LIST OF PUBLICATIONS CITED BY APPLICANT
(Use several sheets if necessary)

JUN 16 2003

PTO
PATENT & TRADEMARK OFFICE

RECEIVED
JUN 18 2003
FBI CENTER 6801-3000

U.S. PATENT DOCUMENTS

EXAMINER NOTES	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
RG	A0	6,210,912 B1	04/01	Koyama et al.	435	7.4

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO

OTHERS (including Author, Title, Date, Pertinent Pages, Etc.)

RG	A1	Bianco, F.J. et al. "Matrix metalloproteinase-9 expression in bladder washes from bladder cancer patients predicts pathological stage and grade." <i>Clinical Cancer Research</i> 4(10):3011-6 (Dec. 1998).
RG	A2	Durkan, G.C. et al. "Prognostic significance of matrix metalloproteinase -1 and tissue inhibitor of metalloproteinase-1 in voided urine samples from patients with transitional cell carcinoma of the bladder." <i>Clinical Cancer Research</i> 7(11):3450-6 (Nov. 2001).
	A3	Kanno, N. et al. "Effects of epidermal growth factor on the invasion activity of the bladder cancer cell line." <i>Journal of Urology</i> 159(2):586-90 (Feb. 1998).
	A4	Koshida, K. et al. "Prospects for molecular research in the invasion activity of the bladder cancer cell line." <i>Journal of Urology</i> 159(2):586-90 (Feb. 1998).
	A5	Levitt, N.C. et al. "Phase I and pharmacological study of the oral matrix metalloproteinase inhibitor, MMI270 (CGS27023A), in patients with advanced solid cancer." <i>Clinical Cancer Research</i> 7(7):1912-22 (Jul. 2001).
	A6	Mizushima, Y. et al. "Diuretic response to cyclophosphamide in rats bearing a matrix metalloproteinase -9-producing tumour." <i>British Journal of Cancer</i> 78(8):1030-4 (Feb. 1998).
	A7	Özdemir, E. et al. "Role of matrix metalloproteinase-9 in the basement membrane destruction of superficial urothelial carcinomas." <i>Journal of Urology</i> 161(4):1359-63 (Apr. 99).
	A8	Pattari, S.K. et al. "Urine: beyond cytology for detection of malignancy." <i>Diagnostic Cytopathology</i> 27(3):139-42 (Sep. 2002).
✓	A9	Yan, L. et al. "The high molecular weight urinary matrix metalloproteinase (MMP) activity is a complex of gelatinase B/MMP-9 and neutrophil gelatinase-associated lipocalin (NGAL). Modulation of MMP-9 activity by NGAL." <i>Journal of Biological Chemistry</i> 276(40):37258-65 (5 Oct. 2001).

Examiner

RG Titman

Date Considered

7/3/03

*EXAMINER:

Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.